Telara

Leaders in eye neuroprotection, we protect your vision.

Cilastatin, advanced neuroprotection to preserve vision

At Telara Pharma, we develop innovative therapies based on cilastatin, a drug with a strong safety record and a powerful neuroprotective effect on the retina. Our goal is to transform glaucoma treatment through an approach that targets retinal neurodegeneration and inflammation, two key processes that current medicine does not address. Unlike therapies focused solely on reducing intraocular pressure (IOP), our ophthalmic drops directly protect retinal ganglion cells, preserving vision and quality of life.

The Problem

Current glaucoma treatments focus on reducing intraocular pressure (IOP), but they are not neuroprotective and do not halt the progression of the disease. As a result, many patients continue to lose vision: more than 40% do not respond to available medications, and 10% develop total blindness within 7 to 15 years.

The pharmaceutical market offers only therapies that control IOP, without alternatives that protect neurons. Neuroprotection is therefore an essential priority for preventing blindness and preserving quality of life.

Check our Pipeline

Program
More information

Leadership

Our Vision

Our vision includes identifying new therapeutic tools for severe conditions like glaucoma. By repurposing cilastatin, we aim to prevent retinal ganglion cell damage and improve patient outcomes, thereby reduce mortality and morbidity through innovative treatments.

Our Values

We are guided by values of professionalism, responsibility, honesty, tenacity, perseverance, efficiency, respect, and sensitivity.

Our Mission

Telara Pharma's mission is to improve quality of life and reduce hospital stays. We aim to prevent retinal ganglion cell damage, preserve vision, and reduce the need for intensive treatments, enhancing patient well-being and safety.

News

Logotip